ABSTRACT
OBJECTIVES: To compare the safety and diagnostic efficacy of coronary computed tomography angiography (CTA) with exercise electrocardiography (XECG) in triaging patients of low risk acute chest pain. BACKGROUND: Noninvasive assessment of coronary stenosis by CTA may improve early and accurate triage of patients presenting with acute chest pain to the emergency department (ED). METHODS: Low risk patients of possible acute coronary syndrome (ACS) were included in the study. The patients in CTA arm with significant stenosis (≥ 50%) underwent catheterization, while those with no or intermediate stenosis (<50%) were discharged from ED and followed up periodically for six months for major adverse cardiovascular events (MACE). The same protocol was applied for XECG arm. Outcomes included: safety and diagnostic efficacy. RESULTS: A total of 81 (41 CTA and 40 XECG) patients were enrolled. In this study CTA was observed to be 100% sensitive and 95.7% specific in diagnosing MACE in low risk patients of chest pain presenting to the ED, with a PPV of 94.7% and an NPV of 100%.The overall diagnostic efficacy was 97.6%. XECG was observed to be 72.7% sensitive and 96.6% specific in diagnosing MACE with a PPV of 88.9% and NPV of 90.3% in low risk chest pain patients presenting to the ED. The overall diagnostic accuracy was 90%. CONCLUSION: CTA is an excellent diagnostic tool in ED patients with low risk of ACS, with minimum time delay as compared to XECG, and also is safe for triaging such patients.
Subject(s)
Acute Coronary Syndrome/diagnosis , Cardiac-Gated Imaging Techniques , Chest Pain/diagnosis , Coronary Angiography/methods , Coronary Stenosis/diagnosis , Electrocardiography/methods , Tomography, X-Ray Computed/methods , Triage , Acute Coronary Syndrome/diagnostic imaging , Chest Pain/diagnostic imaging , Contrast Media , Coronary Stenosis/diagnostic imaging , Exercise Test , Female , Humans , Iohexol/analogs & derivatives , Male , Middle Aged , Prospective Studies , Risk Assessment , Risk Factors , Sensitivity and SpecificityABSTRACT
Tenecteplase is a genetically engineered product of the Alteplase molecule. Mutations of Alteplase at three locations result in a more fibrin specific thrombolytic agent with a longer half life. Such properties would allow bolus administration, leading to faster reperfusion of occluded arteries. Tenecteplase is equivalent to front loaded Alteplase in terms of mortality and is the only bolus thrombolytic drug for which equivalence has been demonstrated. Tenecteplase seems more potent than Alteplase when symptoms duration is more than 4 hours. Moreover, Tenecteplase significantly reduces the rate of major bleeds and the need for blood transfusion. The efficacy of Tenecteplase may be further improved by reducing re-infarction rate by enoxaparin instead of unfractionated heparin. Several large scale Clinical trials of Tenecteplase in acute myocardial infarction (MI) has been done making this drug truly evidence based. Available randomized studies and international clinical registries reveal that pre hospital thrombolysis by Tenecteplase is as effective as primary angioplasty. In fact Tenecteplase is now included in many prehospital thrombolytic reperfusion protocols, such as the Vienna STEMI registry, The Mayoclinic STEMI protocol and the French FAST-MI registry. Tenecteplase with so many evidence based advantages is a fair option in acute MI patients in whom primary PCI can not be offered due to logistic reasons.
